PExA AB Receives EU Trademark Approval for the Name PExA®
PExA AB has received trademark protection for the name PExA® within the European Union.
PExA AB, which has developed world-unique research instruments for collecting biological samples from the small airways, is pleased to announce that the company has had the trademark PExA® approved and registered within the European Union.
PExA, which is an acronym for Particles in Exhaled Air, describes the company’s patented method that enables non-invasive sampling from the deepest regions of the lungs, where many lung diseases originate and develop before causing irreversible and often fatal damage.
Through the company’s unique combination of applying a specific breathing pattern that generates particles consisting of lung fluid from the alveoli, along with an advanced collection instrument, the innermost parts of the lung can be analyzed non-invasively, completely without tubes and needles.
The company’s customers are currently found within the research market worldwide, consisting of research groups in occupational health and healthcare, as well as pharmaceutical companies and authorities. Clinical studies are currently underway in areas such as asthma, lung cancer, and COPD. The goal is to both increase knowledge about various diseases and to find biomarkers that can diagnose diseases earlier and more accurately than today.
Tomas Gustafsson, CEO of PExA, comments:
- “We continuously work to protect our intellectual property, and in addition to the patents we have already had approved, we have now, with this EU trademark approval, expanded our intellectual property protection. It also provides a good foundation for further international trademark applications for PExA, designated for markets such as the USA and potentially other markets of interest to PExA AB.”
The trademark protection covers PExA’s research instruments as well as future developments in diagnostic instruments for common diseases such as lung cancer and COPD, which align with the company’s long-term goal of reaching a broader global market.
For further information, please contact:
Tomas Gustafsson, CEO, Email: info@pexa.se
About PExA AB:
PExA AB (556956-9246) has developed the PExA 2.1, a patented research instrument that helps researchers intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA’s technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 50 scientific publications, which serve as reference material for PExA’s method. The company’s long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.
PExA’s B share is listed on the Spotlight Stock Market.